drugset
drugset / Trial / NCT00084916

CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase

NCT00084916 ↗

Phase 2 Completed 74 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy such as CCI-779 work in different ways to stop cancer cells from dividing so they stop growing or die. This phase II trial is studying how well CCI-779 works in treating patients with relapsed or refractory acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia in blastic phase

Timeline

Start
2004-04
Primary completion
2007-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Temsirolimus Small molecule — Intravenous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, t(16;16)(p13.1;q22) acute promyelocytic leukemia adult acute lymphoblastic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelomonocytic leukemia myelodysplastic syndrome with excess blasts refractory anemia with excess blasts in transformation